Navigation Links
Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
Date:3/10/2008

sco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva is able to manufacture its products on commercially reasonable terms, whether Anesiva can secure FDA approval for the use of Zingo in adults, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended September 30, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entir
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
2. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
3. Anesiva Appoints Daniel Janney to Board of Directors
4. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
5. Anesiva Announces Completion of Common Stock Offering
6. Anesiva Raises $45 Million in Common Stock Offering
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
11. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... Defense, & Homeland Security), Technology, Payload, Type & ... and segments the global unmanned ground vehicle market ... and forecasting of market sizes. The report also ... and opportunities impacting it along with the adoption ...
(Date:10/18/2014)... The “Human Insulin Market- by Product Type, ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2018” provides a detailed overview ... market trends, and strategies impacting the global human ... of the revenue and share analysis. , The ...
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application ... 2019", analyzes the global market on the basis ... industry details such as the key drivers, current ... , Browse 81 Market Data Tables and 29 ... on “1,6-Hexanediol Market by Application and by Geography ...
(Date:10/18/2014)... The Asia-Pacific hardware encryption display market report defines ... and forecast of revenue. This market was valued $5,154.0 ... million by 2018, at a CAGR of 58.4% from ... the Asia-Pacific hardware encryption market report, to get an ... a glimpse of the segmentation of the market, and ...
Breaking Biology Technology:Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 51,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3
... Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), ... tumor specific data to enhance the value of oncology drugs, today ... 2009. Full details of the Company,s financial results are available in ... , Total revenues for the first quarter of ...
... SINGAPORE, Sept. 14 China Agro-Technology Holdings (OTC ... website which is focused on spotlighting the company,s focus on ... website is located at www.chinaagrotech.com. , , ... Holdings Ltd., headquartered in Singapore, is focused on becoming a ...
... , , ... 14 Tobira Therapeutics Inc., a clinical stage biotechnology ... treatment of life-threatening and life-altering infectious diseases, today announced ... randomized study of TBR-652 in sixty healthy volunteers. ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 5Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2
... calls for policymakers to reduce both nitrogen and phosphorus ... problems in fresh and coastal waters. In the ... argue that dual-nutrient reduction strategies are likely to be ... phosphorus in fresh and coastal water ecosystems. "If ...
... 2009 ― Protecting drinking water and preventing harmful ... many lakes, will require reducing both nitrogen and ... to the sea, management strategies should be implemented ... that focus only on one nutrient will fail. ...
... be exhausting. When fruit flies mate, the females, genes ... an immune reaction starts. This is shown in a ... the scientific publication, Journal of Evolutionary Biology .* ... genomic technology, so-called microarrays, researchers at Uppsala University can ...
Cached Biology News:Nutrient pollution chokes marine and freshwater ecosystems 2
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
... Reduce bench time to just 15 minutes! ... paralles that can be drawn between this exciting ... of instant foods. Instant meals consumed by ... format and are reconstituted by adding water. ...
APO(a) EIA Sample Size: 25 l...
...
Biology Products: